Peter D. Roselt
305 Grattan St
Melbourne, VIC 3000, Australia
Melbourne, VIC 3000, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting.
Journal: RSC advances
Published: January 23, 2026
Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting.
Journal: RSC advances
Published: November 14, 2025
Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters.
Journal: EJNMMI radiopharmacy and chemistry
Published: May 28, 2025
A gallium fluoride-18 complex containing a pentadentate macrocyclic ligand with a dimethylaminostilbene functional group designed for diagnostic imaging of Alzheimer's disease.
Journal: Dalton transactions (Cambridge, England : 2003)
Published: May 13, 2025
Carbonic Anhydrase-IX Is a Specific and Sensitive Theragnostic Target for Imaging and Radioimmunotherapy in Metastatic Colorectal Cancer.
Journal: Gastro hep advances
Published: March 05, 2025
Preclinical evaluation and automated synthesis of [89Zr]ZrDFOSquaramide-girentuximab for diagnostic imaging of carbonic anhydrase IX positive tumours.
Journal: EJNMMI radiopharmacy and chemistry
Published: September 17, 2024
A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents.
Journal: Nature protocols
Published: August 02, 2024
Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological Heterogeneity.
Journal: Molecular imaging and biology
Published: August 01, 2024
Automated synthesis of [89Zr]ZrCl4, [89Zr]ZrDFOSquaramide-bisPh(PSMA) and [89Zr]ZrDFOSquaramide-TATE.
Journal: EJNMMI radiopharmacy and chemistry
Published: March 24, 2024
Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers.
Journal: Journal of medicinal chemistry
Published: July 26, 2023
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
Journal: International journal of radiation oncology, biology, physics
Published: March 15, 2023
Last Updated: 09/26/2026